SCHEMBL15526219

SCHEMBL15526219

CC(=COCCO)C(=O)OCCN(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 2/20 0.43
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM5 P08912 1/20 0.43
CHRNB2 P17787 1/20 0.43
CHRM3 P20309 1/20 0.43
CHRNA4 P43681 1/20 0.43
DNM1 Q05193 1/20 0.36
BCHE P06276 2/20 0.35
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
PHLPP2 Q6ZVD8 1/20 0.34
MAPT P10636 3/20 0.33
NPSR1 Q6W5P4 1/20 0.32
ALDH1A1 P00352 3/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8629629 0.86 TSHR (0.39) THRB
SCHEMBL27748757 0.83 DNM1 (0.39) CHRM1CHRM2CHRM4CHRM5CHRNB2
SCHEMBL22207367 0.83 CHRM2 (0.37) CHRM1CHRM2CHRM3
SCHEMBL26980911 0.81 ACHE (0.37) SMN1; SMN2ALDH1A1GAATHRB
SCHEMBL937816 0.79 GLO1 (0.42) SMN1; SMN2MAPTNPSR1ALDH1A1CYP2C19
SCHEMBL340908 0.78 CHRM1 (0.52) CHRM1CHRM2CHRM4CHRM5CHRNB2
SCHEMBL28150485 0.78 CHRM1 (0.52) CHRM1CHRM2CHRM4CHRM5CHRNB2
SCHEMBL8007103 0.78 ALDH1A1 (0.47) ALDH1A1
SCHEMBL28968670 0.78 THRB (0.49) CA1CA2ALDH1A1THRB
Water SCHEMBL21326730 0.77 CHRM1 (0.50) CHRM1CHRM2CHRM4CHRM5CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4299133-A2 COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTICS VIIV Healthcare Company (US) 2024-01-03 EP disclosed
US-20220211714-A1 COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTICS BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA 2022-07-07 US disclosed
US-11311545-B2 Compositions and methods for the delivery of therapeutics BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2022-04-26 US disclosed
US-11117904-B2 Compositions and methods for the delivery of therapeutics VIIV HEALTHCARE COMPANY (US) 2021-09-14 US disclosed
US-20210230186-A1 COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTICS VIIV HEALTHCARE COMPANY 2021-07-29 US disclosed
US-10400262-B2 Analyte sensing for eye injuries and conditions THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2019-09-03 US disclosed
EP-3474857-A2 COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTICS VIIV Healthcare Company (US) 2019-05-01 EP disclosed
US-20180105857-A1 Analyte Sensing for Eye Injuries and Conditions CARLE HEALTH CARE INCORPORATED D/B/A CARLE PHYSICIAN GROUP 2018-04-19 US disclosed
WO-2017223280-A2 COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTICS VIIV HEALTHCARE COMPANY (US) 2017-12-28 WO disclosed
US-20170304308-A1 Compositions and Methods for the Delivery of Therapeutics BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA 2017-10-26 US disclosed
EP-3203995-A1 COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTICS Board of Regents of the University of Nebraska (US) 2017-08-16 EP disclosed
US-20170165271-A1 Compositions and Methods for the Delivery of Therapeutics BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA 2017-06-15 US disclosed
EP-3110422-A1 COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTICS Board of Regents of the University of Nebraska (US) 2017-01-04 EP disclosed
US-20160136105-A1 Compositions and Methods for the Delivery of Therapeutics NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-05-19 US disclosed
WO-2016057866-A1 COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTICS BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2016-04-14 WO disclosed
WO-2015127437-A1 COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTICS THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2015-08-27 WO disclosed
US-20150151006-A1 Compositions and Methods for Gene Therapy NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-06-04 US disclosed
US-20150125401-A1 SMALL MAGNETITE THERAPEUTICS AND METHODS OF USE THEREOF BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA 2015-05-07 US disclosed
US-20150079007-A1 TUNABLE MULTIMODAL NANOPARTICLES AND METHODS OF USE THEREOF BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2015-03-19 US disclosed
WO-2013159092-A1 TUNABLE MULTIMODAL NANOPARTICLES AND METHODS OF USE THEREOF BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2013-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210230186-A1 COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTICS HAVCR2, MTREX, MAVS CHRM1 4845/4885CHRM2 4775/4885CHRM4 4363/4885
US-20160136105-A1 Compositions and Methods for the Delivery of Therapeutics HAVCR2, MTREX, MAVS CHRM1 4845/4885CHRM2 4775/4885CHRM4 4363/4885
US-20150079007-A1 TUNABLE MULTIMODAL NANOPARTICLES AND METHODS OF USE THEREOF CD47, AIP, PSMA3 CHRM1 2809/4885CHRM2 3353/4885CHRM4 3587/4885
US-20170304308-A1 Compositions and Methods for the Delivery of Therapeutics HAVCR2, MTREX, MAVS CHRM1 4845/4885CHRM2 4775/4885CHRM4 4363/4885
US-11117904-B2 Compositions and methods for the delivery of therapeutics HAVCR2, MTREX, MAVS CHRM1 4845/4885CHRM2 4775/4885CHRM4 4363/4885
US-20170165271-A1 Compositions and Methods for the Delivery of Therapeutics HAVCR2, MTREX, MAVS CHRM1 4845/4885CHRM2 4775/4885CHRM4 4363/4885
US-11311545-B2 Compositions and methods for the delivery of therapeutics HAVCR2, MTREX, MAVS CHRM1 4845/4885CHRM2 4775/4885CHRM4 4363/4885
US-20220211714-A1 COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTICS HAVCR2, MTREX, MAVS CHRM1 4845/4885CHRM2 4775/4885CHRM4 4363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.